Success Metrics

Active Trials
6(86%)

Phase Distribution

Ph phase_3
4
57%
Ph phase_2
2
29%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Recruiting5
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 34 (57.1%)

Trials by Status

active_not_recruiting114%
not_yet_recruiting114%
recruiting571%

Recent Activity

6 active trials
Showing 5 of 7
recruitingphase_3

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094
recruitingphase_2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311
recruitingphase_2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177
recruitingphase_3

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270
not_yet_recruitingphase_3

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

NCT07564141
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07166094Phase 3

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Recruiting
NCT07539311Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

Recruiting
NCT07288177Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Recruiting
NCT07225270Phase 3

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Recruiting
NCT07564141Phase 3

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Not Yet Recruiting
NCT06619236Phase 3

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Active Not Recruiting
NCT05579366Phase 1

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7